Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination.
The ligand to receptor activator of NF-kappaB (RANK-L)/RANK interaction has been implicated in CD40 ligand/CD40-independent T cell priming by dendritic cells. In this report, we show that the coadministration of the RANK-L gene with a Trypanosoma cruzi gene markedly enhances the induction of Trypanosoma Ag-specific CD8(+) T cells and improves the DNA vaccine efficacy. A similarly potent adjuvant effect of the RANK-L gene on the induction of Ag-specific CD8(+) T cells was also observed when recombinant influenza virus expressing murine malaria Ag was used as an immunogen. In contrast, the coadministration of the CD40L gene was not effective in these systems. Our results demonstrated, for the first time, the potent immunostimulatory effect of the RANK-L gene to improve the CD8(+) T cell-mediated immunity against infectious agents.
Miyahira
Yasushi
Y
Department of Molecular and Cellular Parasitology, Juntendo University School of Medicine, Tokyo, Japan. miyahira@med.juntendo.ac.jp
Akiba
Hisaya
H
Katae
Masaharu
M
Kubota
Kaori
K
Kobayashi
Seiki
S
Takeuchi
Tsutomu
T
García-Sastre
Adolfo
A
Fukuchi
Yoshinosuke
Y
Okumura
Ko
K
Yagita
Hideo
H
Aoki
Takashi
T
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D023201:CD40 Ligand / Q000096:biosynthesis / Q000235:genetics; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D002352:Carrier Proteins / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D002460:Cell Line; D045744:Cell Line, Tumor; D014355:Chagas Disease / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D016328:NF-kappa B / Q000235:genetics* / Q000378:metabolism; D009439:Neuraminidase / Q000008:administration & dosage / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D018124:Receptors, Tumor Necrosis Factor; D014349:Trypanosoma cruzi / Q000235:genetics / Q000276:immunology; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D002352:Carrier Proteins; D018984:Epitopes, T-Lymphocyte; D006023:Glycoproteins; D007252:Influenza Vaccines; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; C505687:Tnfrsf11a protein, mouse; C506031:Tnfrsf11b protein, mouse; C505689:Tnfsf11 protein, mouse; D017778:Vaccines, Combined; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D023201:CD40 Ligand; C069715:trans-sialidase; D009439:Neuraminidase